Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 24465249)

1.

Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial.

Tsujino N, Nemoto T, Morita K, Katagiri N, Ito S, Mizuno M.

Clin Psychopharmacol Neurosci. 2013 Dec;11(3):132-6. doi: 10.9758/cpn.2013.11.3.132. Epub 2013 Dec 24.

2.

Challenges in the early detection and intervention of the psychosis-risk syndrome.

Lv H, Zhou X, Zhao J.

Shanghai Arch Psychiatry. 2015 Feb 25;27(1):45-7. doi: 10.11919/j.issn.1002-0829.215016.

3.

Ethical, Legal, and Clinical Considerations when Disclosing a High-Risk Syndrome for Psychosis.

Mittal VA, Dean DJ, Mittal J, Saks ER.

Bioethics. 2015 Feb 17. doi: 10.1111/bioe.12155. [Epub ahead of print]

PMID:
25689542
4.

Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program.

Tso IF, Taylor SF, Grove TB, Niendam T, Adelsheim S, Auther A, Cornblatt B, Carter CS, Calkins R, Ragland JD, Sale T, McFarlane WR.

Early Interv Psychiatry. 2014 Dec 21. doi: 10.1111/eip.12209. [Epub ahead of print]

PMID:
25529847
5.

Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.

Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T.

Cochrane Database Syst Rev. 2013 Mar 28;3:CD007726. doi: 10.1002/14651858.CD007726.pub2. Review.

PMID:
23543555
6.

Antipsychotic interventions in prodromal psychosis: safety issues.

Liu CC, Demjaha A.

CNS Drugs. 2013 Mar;27(3):197-205. doi: 10.1007/s40263-013-0046-1. Review.

PMID:
23436256
7.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster RH, Goa KL.

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

PMID:
23338224
8.

Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.

Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM.

J Clin Psychopharmacol. 2013 Feb;33(1):18-23. doi: 10.1097/JCP.0b013e31827cb017.

PMID:
23277261
9.

Benzodiazepines for schizophrenia.

Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD006391. doi: 10.1002/14651858.CD006391.pub2. Review.

PMID:
23152236
10.

Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2004;4(7):1-98. Epub 2004 Jun 1.

11.

A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.

Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:110-4. doi: 10.1016/j.pnpbp.2012.09.010. Epub 2012 Sep 27.

PMID:
23022672
12.
13.

Paliperidone palmitate for schizophrenia.

Nussbaum AM, Stroup TS.

Cochrane Database Syst Rev. 2012 Jun 13;6:CD008296. doi: 10.1002/14651858.CD008296.pub2. Review.

PMID:
22696377
14.

Quetiapine: a review of its use in the management of bipolar depression.

Sanford M, Keating GM.

CNS Drugs. 2012 May 1;26(5):435-60. doi: 10.2165/11203840-000000000-00000. Review.

PMID:
22519923
15.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006103. doi: 10.1002/14651858.CD006103.pub6. Review.

PMID:
22513936
16.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
17.

Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.

Bechdolf A, Müller H, Stützer H, Wagner M, Maier W, Lautenschlager M, Heinz A, de Millas W, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Brüne M, Krüger-Özgürdal S, Wobrock T, Riedel M, Klosterkötter J; PREVENT study group.

Schizophr Bull. 2011 Sep;37 Suppl 2:S111-21. doi: 10.1093/schbul/sbr083.

18.

Antidepressants for agitation and psychosis in dementia.

Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191. doi: 10.1002/14651858.CD008191.pub2. Review.

PMID:
21328305
19.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
20.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk